Log In
Print
BCIQ
Print
Print this Print this
 

ondansetron (TO-2061) (formerly Setrodon)

  Manage Alerts
Collapse Summary General Information
Company Transcept Pharmaceuticals Inc.
DescriptionLow-dose formulation of ondansetron, a serotonin (5-HT3) receptor antagonist
Molecular Target Serotonin (5-HT3) receptor
Mechanism of ActionSerotonin (5-HT3) receptor antagonist
Latest Stage of DevelopmentPhase II
IndicationObsessive compulsive disorder (OCD)
Partner

 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today